{
  "agent_name": "arv_guidelines_agent_v2",
  "system_prompt": [],
  "provider": "openai",
  "model": "gpt-4o-mini",
  "tools": [
    "arv_text_search"
  ],
  "messages": [
    {
      "parts": [
        {
          "content": "You are a helpful clinical decision support assistant for HIV care in Kenya.\n\nUse the search tool to find relevant information from the Kenya ARV Guidelines and related clinical documents before answering questions.\n\nIf you find specific guidance through search, use it to provide accurate, guideline-aligned answers.\n\nAlways include references by citing the filename of the source material you used.\nWhen citing the reference, replace the filename with the page\n\nFormat references as:\n[DOCUMENT TITLE][PAGE]\n\nIf the search does not return relevant results, clearly state that the guidelines do not specify this and provide safe, general clinical guidance consistent with standard HIV care principles.\n\nDo not make up recommendations that are not supported by the guidelines.",
          "timestamp": "2026-02-11T00:06:03.540663+00:00",
          "dynamic_ref": null,
          "part_kind": "system-prompt"
        },
        {
          "content": "What is the recommended intensive phase treatment regimen for drug-susceptible TB in adults and adolescents?",
          "timestamp": "2026-02-11T00:06:03.540673+00:00",
          "part_kind": "user-prompt"
        }
      ],
      "instructions": null,
      "kind": "request"
    },
    {
      "parts": [
        {
          "tool_name": "arv_text_search",
          "args": "{\"query\":\"intensive phase treatment regimen drug-susceptible TB adults adolescents\"}",
          "tool_call_id": "call_IJEiIUBNSkyn3entGdvcy0Iz",
          "id": null,
          "part_kind": "tool-call"
        }
      ],
      "usage": {
        "input_tokens": 274,
        "cache_write_tokens": 0,
        "cache_read_tokens": 0,
        "output_tokens": 28,
        "input_audio_tokens": 0,
        "cache_audio_read_tokens": 0,
        "output_audio_tokens": 0,
        "details": {
          "accepted_prediction_tokens": 0,
          "audio_tokens": 0,
          "reasoning_tokens": 0,
          "rejected_prediction_tokens": 0
        }
      },
      "model_name": "gpt-4o-mini-2024-07-18",
      "timestamp": "2026-02-11T00:06:04+00:00",
      "kind": "response",
      "provider_name": "openai",
      "provider_details": {
        "finish_reason": "tool_calls"
      },
      "provider_response_id": "chatcmpl-D7s20EpO5NSdSDH299SzDH9gJjoB5",
      "finish_reason": "tool_call"
    },
    {
      "parts": [
        {
          "tool_name": "arv_text_search",
          "content": [
            "  \nTB/HIV Co -infection, Prevention and Management  \n \n8 - 17 Table 8.8 Cont.  \n1. For patients on 2nd line ART, subsequent regimens, drug intolerance, or nonstandard drugs who require \nregimen change because of TB treatment, consult the Regional or National HIV Clinical TWG (Uliza Hotline \n0726 460 000; https://nhcsc.nascop.org/clinicalform ) \n2. Contact  the Regional or National HIV Clinical TWG (Uliza Hotline 0726 460 000; \nhttps://nhcsc.nascop.org/clinicalform ) for guidance on urgent collection of DRT samples  \n3. Use \u201csuper -boosted\u201d LPV/r by adding additional ritonavir to manage the drug interaction between LPV/r \nand rifampicin (see Annex 10 for dosing recommendations). Two weeks after TB treatment is completed \nthe child should go back to standard LPV/r dosing.  \n ",
            " \nTB/HIV Co -infection, Prevention and Management  \n \n8 - 7 \n Table 8.2: Drug Susceptible TB Treatment Regimen for Children, Adolescents and Adults  \nTB disease category  Recommended regimen  \nIntensive phase        Continuation phase  \nAll forms of TB except TB meningitis, bone \nand joint TB (osteoarticular TB)  2 RHZE  4 RH  \nTB meningitis   \nOsteoarticular TB  2 RHZE  10 RH  \nDrug resistant TB  Refer to a DRTB Clinical Team  \n\u25cf Follow up smears should be done for all bacteriologically confirmed pulmonary TB cases at end of \nmonth 2, 5 and 6 of TB treatment using smear microscopy  \n\u25cf Follow up of RR TB and DR TB should be done as per PMDT guidelines  \n\u25cf Patients taking isoniazid containing regimen should also be given Pyridoxine (Vitamin B6) daily for \nthe duration of treatment to reduce the risk of developing peripheral neuropathy (see Annex 10 for \npyridoxine dosing)  \nOnce TB treatment is started it should be completed; unless another definitive diagnosis (like lung \ncancer) is established and TB is ruled out.  \n \n \n \n ",
            "  \nTB/HIV Co -infection, Prevention and Management  \n \n9 - 3 B. Recommended first -line ART in HIV/HBV co -infection  \nThe recommended first -line ART in adolescents and adults with HIV/HBV co -infection \nis TDF + 3TC + DTG, including for women and adolescent girls of childbearing potential  \n \nTreatment with both TDF (or TAF) and 3TC is recommended as 3TC without TDF or TAF will \nresult in rapid emergence of resistance. In case of renal impairment (as assessed by creatinine \nclearance), the dose of TDF and 3TC should be adjusted (Table 9.3).  \nTable 9.2: Summary of Initial Clinical and Labora tory Evaluation in HIV/HBV Co -infection  \n Findings  Action  \nHistory  Alcohol use, cigarette \nsmoking, intravenous drug \nuse, risky sexual practices, \nanorexia, right upper \nquadrant pain, jaundice, early \nsatiety, haematemesis, dark \nstool, bleeding, pruritus  Assess, counsel and support to stop taking \nalcohol; counsel and support smoking \ncessation; counsel and provide or refer for \nharm reduction interventions  \ndiscuss or refer to a consultant for additional \nevaluation and management  \nPhysical \nexamination  Enlarged liver, enlarged \nspleen, ascites, scratch marks  Evidence of established chronic liver disease, \ncloser follow -up due to increased risk of \nhepatotoxicity.  \ndiscuss or refer to a consultant for additional \nevaluation and management  \nALT  If elevated, may point to \nactive liver disease. Exclude \nother causes of elevation of \nliver enzymes  Every effort should be made to assess for \nother liver function (albumin and INR), \nespecially in symptomatic patients. However, \nthis should not delay initiation of ART  \nCreatinine  Calculate creatinine clearance  In HIV/HBV co -infection, TDF is indicated \neven in patients with CrCl < 50 ml/min. In \nsuch patients, avoid FDCs. Instead administer \nthe ART as single drugs to allow for dosage \nadjustment as shown in Table 9.3  \nComorbidities  HCV antibody, random blood \nsugar, lipid profile, alcoholic \nand non -alcoholic liver \ndisease, hepatocellular \ncarcinoma (family history)  Consult/Refer the patient for additional \ninvestigations where these are suspected  \n \n  ",
            "  \nKenya HIV Prevention and Treatment Guidelines, 2022  \n 8 - 14 \u25cf Patients who are already on ART  \no Start TB treatment immedi ately  \no Continue ART, assessing for treatment failure and making any required \nadjustments to the ART regimen based on drug -drug interactions (Table 8.7)  \no Monitor closely for IRIS (Annex 16)  \n\u25cf Patient being treated concurrently for TB and HIV require close monitoring for \ntoxicity  \n\u25cf MDR TB and HIV co -infection should be managed in settings where close toxicity \nmonitoring and follow up by experienced clinicians or multi -disciplinary team is \npossible       \nPreferred ART regimens for patients with TB/HIV co -infecti on are summarized in Tables 8.6 - 8.8. \nTable 8.6: Preferred ART Regimens for TB/HIV Co -infection for Patients Newly Initiating 1st \nLine ART 1 \nAge  Weight  1st Line ART if TB/HIV Co -infection  \nBirth to 4 \nweeks  Any  Start anti -TB treatment immediately; start ART after 4 weeks \nof age, once tolerating anti -TB drugs (follow the regimen \nrecommendations for children \u2265 4 weeks old)  \n> 4 weeks to < \n15 years  < 30 kg  \u25cf ABC + 3TC + DTG  \n\u25cf Increase DTG dosing frequency to twice daily for duration \nof rifampicin -containing TB treatment and for an additional \n2 weeks after TB treatment is completed, then revert to \nonce daily dosing  \n\u2265 30 kg  \u25cf Give TDF/3TC/DTG FDC morning + DTG 50mg evening for \nduration of rifampicin -containing TB treatment and for an \nadditional 2 weeks after TB treatment is completed, then \nrevert to TDF/3TC/DTG FDC once daily  \n\u2265 15 years  Any  \u25cf Give TDF/3TC/DTG FDC morning + DTG 50mg evening for \nduration of rifampicin -containing TB treatment and for an \nadditional 2 weeks after TB treatmen t is completed, then \nrevert to TDF/3TC/DTG FDC once daily  \n1 Refer to Annex 10 for weight -based ARV dosing  \n \n \n  ",
            "  \nTB/HIV Co -infection, Prevention and Management  \n \n8 - 15 Table 8.7: Preferred ART Regimens for Patients who Develop TB while Virally Suppressed on \n1st Line ART 1,2 \nCurrent \nRegimen3  Recommended Substitution  \nPI/r -based4 All ages  \u25cf Switch from PI/r to DTG and continue this regimen even after \ncompleting TB treatment. Follow DTG dosing as below  \n\u25cf If it is not possible to switch to DTG:  \no Children < 30 kg requiring PI/r -based ART should receive \nLPV/r with additional ritonavir super -boosting for the duration \nof rifampicin -based TB therapy, reverting to standard LPV/r \ndosing 2 weeks after completing TB treatment  \no Patients \u2265 30 kg who cannot switch to DTG should be switched \nto EFV -based ART and maintained on EFV -based ART after \ncompletion of TB treatment  \nRAL -based  All ages Switch from RAL to double -dose DTG dosing during TB treatment and \nmaintain on DTG after completion of TB treatment  \nDTG -based  All ages   \nAdminister the double -dose of DTG (i.e., the standard weight -based \ndose of DTG given twice daily) while taking rifampicin containing TB \ntreatment. Two weeks after completion of TB treatment revert to the \nrecommended DTG dose once daily.  \n1 Always assess for HIV treatment failure in patients who develop TB after being on ART for \u2265 6 \nmonths. For patients failing 1st line ART refer to Table 8.8 for recommended 2nd line regimens  \n2 For patients on 2nd line ART, subsequent regimens, or nonstandard drugs who require regimen \nchange because of TB treatment, consult the Regional or National HIV Clinical TWG (Uliza Hotline \n0726  460 000; https://nhcsc.nascop.org/clinicalform ) \n3 NRTIs in the patient\u2019s current regimen do not require any adjustments with anti -TB treatment  \n4 Use \u201csuper -boosted\u201d LPV/r by adding additional ritonavir to manage the drug interaction between \nLPV/r and rifampicin (see Annex 10 for dosing recommendations)  \n \n  "
          ],
          "tool_call_id": "call_IJEiIUBNSkyn3entGdvcy0Iz",
          "metadata": null,
          "timestamp": "2026-02-11T00:06:05.930033+00:00",
          "part_kind": "tool-return"
        }
      ],
      "instructions": null,
      "kind": "request"
    },
    {
      "parts": [
        {
          "content": "The recommended intensive phase treatment regimen for drug-susceptible tuberculosis (TB) in adults and adolescents consists of:\n\n- **2 RHZE**: This signifies the use of the following medications during the intensive phase:\n  - R = Rifampicin\n  - H = Isoniazid\n  - Z = Pyrazinamide\n  - E = Ethambutol\n\n**Continuation Phase:** After the intensive phase, the continuation phase should consist of **4 RH**, which includes:\n- R = Rifampicin\n- H = Isoniazid\n\nSpecific considerations are noted for patients with TB meningitis or osteoarticular TB, which require a longer continuation phase of **10 RH**.\n\nIt's important to monitor patients closely throughout treatment and ensure completion unless another definitive diagnosis is established. \n\nReferences: [TB/HIV Co-infection, Prevention and Management][8-7].",
          "id": null,
          "part_kind": "text"
        }
      ],
      "usage": {
        "input_tokens": 2447,
        "cache_write_tokens": 0,
        "cache_read_tokens": 0,
        "output_tokens": 182,
        "input_audio_tokens": 0,
        "cache_audio_read_tokens": 0,
        "output_audio_tokens": 0,
        "details": {
          "accepted_prediction_tokens": 0,
          "audio_tokens": 0,
          "reasoning_tokens": 0,
          "rejected_prediction_tokens": 0
        }
      },
      "model_name": "gpt-4o-mini-2024-07-18",
      "timestamp": "2026-02-11T00:06:06+00:00",
      "kind": "response",
      "provider_name": "openai",
      "provider_details": {
        "finish_reason": "stop"
      },
      "provider_response_id": "chatcmpl-D7s22elSIB0mlliFV1ckjLwJjy5XV",
      "finish_reason": "stop"
    }
  ],
  "source": "ai-generated"
}